Skip to main content

Table 2 Descriptive statistics grouped by recovery trajectory for SR-mTBI patients assessed using BG-SA at initial clinical assessment (n = 79) and at initial and discharge assessments (n = 45)

From: Preliminary Evidence for the Clinical Utility of Tactile Somatosensory Assessments of Sport-Related mTBI

Descriptive statistics for patients assessed with BG-SA at initial SR-mTBI assessment only
  Total (n = 79) Resolution ≤14 days (n = 22) Resolution > 14 days (n = 41) Lost to follow-up (n = 16)
Sexa
 Male 60 (76%) 21.0 (95%) 28 (68%) 11.0 (69%)
 Female 19 (24%) 1.0 (5%) 13 (32%) 5.0 (31%)
Sporta
 Rugby codes 54 (68%) 20 (91%) 26 (63%) 8 (50%)
 Others 15 (19%) 1 (5%) 10 (24%) 4 (25%)
 Football 10 (13%) 1 (5%) 5 (12%) 4 (25%)
Ageb 19.0 [16.0; 23.0] 19.0 [16.0; 23.0] 19.0 [15.0; 23.0] 20.5 [16.8; 30.8]
Days until initial assessmentb 10.0 [5.5; 14.5] 6.5 [4.0; 10.0]* 11.0 [6.0; 17.0] 11.0 [6.0; 14.0]
Days until asymptomaticb 20.0 [12.0; 34.5] 10.5 [6.0; 12.0] 30.0 [20.0; 45.0]
Initial PSTb 11.0 [6.0; 17.0] 6.0 [3.25; 7.0]*,† 14.0 [7.0; 17.0] 16.0 [10.5; 18.0]
Initial symptom severityb 20.0 [8.5; 42.0] 8.0 [5.0; 14.3]*,† 25.0 [13.0; 47.0] 36.0 [23.5; 48.3]
TOJ performance (ms)b 29.0 [20.3; 40.2] 26.5 [17.1; 32.9] 29.0 [20.5; 40.6] 32.7 [22.5; 53.8]
TOJc performance (ms)b 59.9 [34.1; 84.4] 57.8 [40.7; 77.5] 63.9 [32.0; 86.2] 54.9 [42.2; 84.1]
DUR performance (ms)b 50.0 [29.2; 66.7] 50.0 [41.7; 72.9] 50.0 [25.0; 66.7] 45.8 [25.0; 72.9]
Descriptive statistics for participants assessed with BG-SA at initial and discharge SR-mTBI assessments
  Total (n = 45) Resolution ≤14 days (n = 15) Resolution > 14 days (n = 30)  
Sexa
 Male 35 (78%) 14.0 (93%) 21 (70%)  
 Female 10 (22%) 1.0 (7%) 9 (30%)  
Sporta
 Rugby codes 33 (73%) 13 (87%) 20 (66%)  
 Others 8 (18%) 1 (7%) 7 (23%)  
 Football 4 (9%) 1 (7%) 3 (10%)  
Ageb 19.0 [16.0; 23.0] 19.0 [15.5; 23.0] 19.5 [16.0; 24.0]  
Days until initial assessmentb 10.0 [5.0; 12.0] 10.0 [4.0; 10.0] 11.0 [6.0; 16.5]  
Days until asymptomaticb 20.0 [12.0; 32.0] 10.0 [5.0; 12.0] 27.5 [20.0; 42.5]  
Initial PSTb 7.0 [5.0; 14.0] 5.0 [2.5; 7.0] 11.0 [6.25; 17.0]  
Discharge PSTb 1.0 [0.0; 2.0] 0.0 [0.0; 1.0] 1.0 [0.25; 3.0]  
Initial symptom severityb 15.0 [7.0; 29.0] 7.0 [3.0; 11.0] 22.0 [10.5; 44.5]  
Discharge symptom severityb 1.0 [0.0; 2.0] 0.0 [0.0; 1.0] 1.0 [0.25; 4.0]  
TOJ performance (ms)b 27.2 [18.2; 36.8] 24.7 [15.7; 31.9] 28.3 [20.2; 40.4]  
TOJc performance (ms)b 55.6 [34.9; 82.5] 51.3 [42.3; 60.5] 66.1 [32.7; 85.3]  
DUR performance (ms)b 50.0 [25.0; 66.7] 41.7 [29.2; 54.2] 50.0 [29.2; 66.7]  
  1. Notes: aFrequency (%), bmedian [25th percentile; 75th percentile], *Dunn’s post hoc comparison of Kruskal-Wallis tests p < 0.05 ≤ 14-day vs > 14-day resolution, Dunn’s post hoc comparison of Kruskal-Wallis tests p < 0.05 ≤ 14 days vs lost to follow-up, Dunn’s post hoc comparison of Kruskal-Wallis tests > 14-day resolution vs lost to follow-up, Mann-Whitney U p < 0.05 for ≤14-day vs > 14-day resolution